|Bid||0.00 x 3100|
|Ask||0.00 x 1400|
|Day's Range||20.52 - 20.55|
|52 Week Range||15.27 - 21.01|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 20, 2019 - Mar 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||21.93|
BEIJING, Jan. 18, 2019 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced the completion of its merger (the “Merger”) with IK Healthcare Merger Limited (“Merger Sub”), a wholly owned subsidiary of IK Healthcare Investment Limited (“Parent”), pursuant to the previously announced agreement and plan of merger dated as of March 26, 2018 and amended pursuant to Amendment No. 1 thereto dated as of May 29, 2018, Amendment No. 2 thereto dated as of September 25, 2018 and Amendment No. 3 thereto dated as of December 14, 2018 (the “Merger Agreement”), by and among the Company, Parent and Merger Sub. As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent.
Jan 14 (Reuters) - Suning.Com Co Ltd: * SAYS UNIT AND YUNFENG INVESTMENT III LTD TO SET UP YUNFENG FUND III IN ORDER TO SET UP PRIVATE EQUITY FUND WORTH UP TO $2.5 BILLION WITH PARTNERS * UNIT TO INVEST ...
Hedge funds and other investment firms run by legendary investors like Israel Englander and Ray Dalio are entrusted to manage billions of dollars of accredited investors’ money because they are without peer in the resources they use to identify the best investments for their chosen investment horizon. Moreover, they are more willing to invest a […]
BEIJING, Dec. 20, 2018 -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG), a major provider in China’s fast growing private preventive healthcare.
BEIJING, Dec. 06, 2018 -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (Nasdaq: KANG), a major provider in China’s fast growing private preventive healthcare.
BEIJING, Nov. 29, 2018 (GLOBE NEWSWIRE) -- iKang Healthcare Group, Inc. (“iKang” or the “Company”) (KANG), announced today that its board of directors (the “Board of Directors”) has unanimously approved the extension of its Rights Agreement, presently scheduled to expire on December 2, 2018, for another year. As previously disclosed, the termination date under the Merger Agreement has passed. The Company cautions its shareholders and others considering trading its securities that there is no indication or assurance that Parent and Merger Sub will waive the closing condition related to dissenting shareholders in Section 7.02(e) of the Merger Agreement and proceed to consummate the Merger.
LONDON, UK / ACCESSWIRE / July 16, 2018 / If you want a free Stock Review on IQV sign up now at www.wallstequities.com/registration. WallStEquities.com has selected the following Medical Laboratories and Research stocks for review this morning: iKang Healthcare Group Inc. (NASDAQ: KANG), Invitae Corp. (NYSE: NVTA), IQVIA Holdings Inc. (NYSE: IQV), and Laboratory Corp. of America Holdings (NYSE: LH).
NEW YORK, NY / ACCESSWIRE / June 22, 2018 / iKang Healthcare Group, Inc. Sponsored ADR Class A (NASDAQ: KANG ) will be discussing their earnings results in their Q4 Earnings Call to be held on June 22, ...
Gains were broad based as eight out of nine sectors finished the trading session in green. WallStEquities.com has initiated research reports on the following Medical Laboratories & Research stocks: DexCom Inc. (NASDAQ: DXCM), Exact Sciences Corp. (NASDAQ: EXAS), iKang Healthcare Group Inc. (NASDAQ: KANG), and Invitae Corp. (NYSE: NVTA).
NEW YORK , April 24, 2018 /PRNewswire/ -- Bravo Brio Restaurant Group, Inc. (BBRG) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties in connection with the proposed ...
The Law Offices of Vincent Wong are investigating the Board of Directors of iKang Healthcare Group, Inc. for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to a consortium of entities led by CEO and Chairman Lee Ligang Zhang and Vice Chairman of the Board Boquan He.